Motley Fool Wealth Management LLC Sells 6,323 Shares of Kenvue Inc. (NYSE:KVUE)

Motley Fool Wealth Management LLC trimmed its stake in shares of Kenvue Inc. (NYSE:KVUE) by 7.6% in the fourth quarter, HoldingsChannel reports. The firm owned 77,404 shares of the company’s stock after selling 6,323 shares during the quarter. Motley Fool Wealth Management LLC’s holdings in Kenvue were worth $1,671,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Golden State Equity Partners boosted its position in Kenvue by 12.4% during the fourth quarter. Golden State Equity Partners now owns 27,262 shares of the company’s stock worth $587,000 after purchasing an additional 3,004 shares during the period. Truist Financial Corp lifted its holdings in shares of Kenvue by 55.4% during the fourth quarter. Truist Financial Corp now owns 833,310 shares of the company’s stock worth $17,941,000 after buying an additional 297,178 shares in the last quarter. Bahl & Gaynor Inc. lifted its holdings in shares of Kenvue by 4.8% during the fourth quarter. Bahl & Gaynor Inc. now owns 262,992 shares of the company’s stock worth $5,662,000 after buying an additional 12,082 shares in the last quarter. Jackson Hole Capital Partners LLC acquired a new stake in shares of Kenvue during the fourth quarter worth $481,000. Finally, State of New Jersey Common Pension Fund D lifted its holdings in shares of Kenvue by 10.7% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 966,624 shares of the company’s stock worth $20,811,000 after buying an additional 93,478 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Down 0.8 %

KVUE stock traded down $0.16 during trading on Friday, hitting $18.86. The company had a trading volume of 15,454,689 shares, compared to its average volume of 13,458,618. The business has a 50-day moving average of $19.84 and a 200-day moving average of $20.13. Kenvue Inc. has a one year low of $17.82 and a one year high of $27.80. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, February 8th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.28 by $0.03. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The business had revenue of $3.67 billion for the quarter, compared to analysts’ expectations of $3.78 billion. The firm’s revenue was down 2.7% compared to the same quarter last year. As a group, analysts expect that Kenvue Inc. will post 1.15 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th will be paid a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 4.24%. The ex-dividend date of this dividend is Tuesday, May 7th.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. William Blair assumed coverage on Kenvue in a research note on Wednesday, April 3rd. They issued a “market perform” rating for the company. The Goldman Sachs Group assumed coverage on Kenvue in a research note on Friday, March 1st. They issued a “neutral” rating and a $20.00 price target for the company. Royal Bank of Canada dropped their price target on Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Friday, February 9th. JPMorgan Chase & Co. dropped their price target on Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 9th. Finally, Sanford C. Bernstein began coverage on Kenvue in a research note on Thursday, April 11th. They set an “underperform” rating and a $18.00 target price for the company. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $24.85.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.